Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | POLA1 | P09884 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17779848 | 0.82 | MGAM (0.36) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL8998094 | 0.74 | MGAM (0.46) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL17779793 | 0.74 | MGAM (0.38) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL12593429 | 0.71 | MGAM (0.38) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL17779795 | 0.71 | MCL1 (0.36) | — | |
| SCHEMBL18469390 | 0.68 | TSHR (0.46) | TSHRGLO1 | |
| SCHEMBL4452690 | 0.68 | TDP1 (0.38) | TSHRGLO1 | |
| SCHEMBL4450446 | 0.68 | TDP1 (0.38) | TSHRGLO1 | |
| SCHEMBL20438201 | 0.67 | MGAM (0.48) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL14305685 | 0.67 | MGAM (0.43) | MGAMGAASIMGAM2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145212-A1 | ACETYL-COA CARBOXYLASE MODULATORS | MONSANTO TECHNOLOGY LLC (US) | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145212-A1 | ACETYL-COA CARBOXYLASE MODULATORS | ACACA, ACACB, ACAT2 | MGAM 225/4885GAA 277/4885SI 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.